Enhanced Effect of Combined Treatment with SMP-534 (Antifibrotic Agent) and Losartan in Diabetic Nephropathy

Eiji Sugaru,Tsutomu Nakagawa,Michiko Ono-Kishino,Jun Nagamine,Teruhisa Tokunaga,Makoto Kitoh,W. Ewan Hume,Ryu Nagata,Mutsuo Taiji

Enhanced Effect of Combined Treatment with SMP-534 (Antifibrotic Agent) and Losartan in Diabetic Nephropathy

2006

Eiji Sugaru
Tsutomu Nakagawa
Michiko Ono-Kishino
Jun Nagamine
Teruhisa Tokunaga
Makoto Kitoh
W. Ewan Hume
Ryu Nagata
Mutsuo Taiji

Background/Aims: Diabetic nephropathy is now the most common cause of end-stage renal disease. It is also clear that the current therapy, angiotensin II blockage, cannot prevent the

Keywords:

Angiotensin II
Losartan
Proteinuria
Diabetic nephropathy
Kidney disease
Renin–angiotensin system
Endocrinology
Internal medicine
Diabetes mellitus
Nephrology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations